Clinical Trials Logo

Hypogonadism clinical trials

View clinical trials related to Hypogonadism.

Filter by:

NCT ID: NCT00240981 Terminated - Sarcopenia Clinical Trials

TOM: Testosterone in Older Men With Sarcopenia

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether testosterone replacement in older men with low testosterone levels will increase muscle strength, improve physical performance and overall sense of well being, and reduce fatigue.

NCT ID: NCT00223860 Completed - Spinal Cord Injury Clinical Trials

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

Start date: July 2001
Phase: N/A
Study type: Interventional

There is evidence that has shown that serum testosterone levels are low in persons with chronic spinal cord injury (SCI). The question arises as to whether the defect in testosterone production is from the hypothalamic pituitary system (part of the brain that plays a role in testosterone release) or from the male testes. Studies to date are inconclusive. This study, will examine if persons with SCI has a normal hormonal regulation of the male hormone testosterone in comparison to persons who are able-bodied. This will help understand the physical and metabolic changes that occur in persons with SCI.

NCT ID: NCT00220298 Completed - Hypogonadism Clinical Trials

Assessment of Long Term Treatment With Testosterone Undecanoate in Males With Hypogonadism

Start date: February 2003
Phase: Phase 3
Study type: Interventional

This study will evaluate the preparation of testosterone undecanoate under conditions which resemble real-life situations.

NCT ID: NCT00204269 Active, not recruiting - Hypogonadism Clinical Trials

Three-Year Trial on a New Testosterone Gel

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The objective of the study is to examine the efficacy and tolerability of a three-year-Testosterone replacement therapy in hypogonadal patients as well as the patient's compliance. The replacement therapy will be performed with a new Testosterone Gel examined in previous trials as Testosteron Gel Wolff.

NCT ID: NCT00202462 Completed - Depressive Disorder Clinical Trials

The Effect of Testosterone on Mood and Quality of Life

Start date: November 2002
Phase: N/A
Study type: Interventional

We hypothesize that testosterone replacement will improve mood and quality of life in older men with low testosterone and mild depression. Study subjects will receive either testosterone gel or a placebo (inactive) gel for 12 weeks. Neither the subject or the investigator will know whether they are receiving placebo or testosterone gel. At the end of the initial 12 week period, all subjects will receive testosterone gel for 12 more weeks. Mood and quality of life measures will be obtained at baseline, at the end of the double-blind phase and at the end of the extension phase (when all subjects receive testosterone.)

NCT ID: NCT00194675 Completed - Clinical trials for Benign Prostatic Hyperplasia

TRADE-Testosterone Replacement and Dutasteride Effectiveness

TRADE
Start date: March 2005
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine whether the combination of the male hormone testosterone [T] in gel form and the oral drug dutasteride [D], used to shrink large prostate glands can safely reduce the size of the prostate gland and symptoms of prostate enlargement (called benign prostatic hyperplasia [BPH]) compared to T treatment alone in men with low testosterone (called hypogonadism).

NCT ID: NCT00193700 Completed - Clinical trials for Primary or Secondary Hypogonadism

Pharmacokinetic Evaluation of Testosterone Gel (1%)

Start date: August 2002
Phase: Phase 1
Study type: Interventional

Measure and evaluate the level of testosterone in blood, and determine the safety and tolerability following daily applications of testosterone gel. Subjects who complete this trial may participate in the extension part (UMD-01-080E).

NCT ID: NCT00193661 Completed - Clinical trials for Primary or Secondary Hypogonadism

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This study is to observe efficacy and safety after T-Gel 1% treatment in delayed puberty adolescents. Subjects who complete this trial may enter a 3 month extension study (UMD-01-090E).

NCT ID: NCT00179517 Completed - Clinical trials for Erectile Dysfunction

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

Start date: June 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if treatment using a medication (anastrozole/Arimidex), which lowers estrogen levels in the blood is better than placebo, a tablet that does not contain any active medication, when combined with testosterone replacement to treat reproductive and sexual dysfunction in men with epilepsy. Anastrozole, the medication that is currently under study, does not, at this time, have FDA approval for use for this indication.

NCT ID: NCT00170339 Completed - Osteoporosis Clinical Trials

Bone Density and Serum Testosterone in Male Methadone Maintained Patients

Start date: April 2005
Phase: N/A
Study type: Observational

This is a pilot study designed to answer the question " Do men who are receiving methadone maintenance therapy have lower spinal bone densities compared with age-matched controls who are not receiving methadone therapy?" The primary aim is to assess whether the mean or median spinal dual-ray energy x-ray absorptiometry (DEXA) scan results are different between these two groups of male patients. Primary measurements include: spinal bone densitometry by DEXA scan. The secondary aim is to examine the role of sex steroids in men receiving methadone maintenance therapy and their association with spinal bone density and sexual dysfunction. Secondary measurements include: serum testosterone, estradiol, lutenizing hormone, albumin, sex hormone binding globulin and Vitamin D levels; age; Brief Sexual Function Inventory; Dietary, smoking/alcohol use and physical activity; Medical history, surgical and medication use; length of time using illicit opiates and time on methadone maintenance therapy.